01—Abstract
Summary
Summary of the 8-K filed January 12, 2026. Cited figures are marked; the original filing is the authoritative source.
Danaher Corporation (NYSE: DHR) furnished an 8-K on January 12, 2026, ahead of a CEO webcast at the J.P.
Morgan Healthcare Conference on January 13, 2026, providing preliminary estimates for Q4 and full-year 2025 results. The filing contains no new financial statements or formal guidance changes; it is a preliminary update that points to a solid close to the year. Management estimates Q4 2025 total revenue growth in the mid-single-digit percent range year-over-year, with non-GAAP core revenue growth at the high end of the previously guided low-single-digit range.
Core growth was partly offset by roughly a low-single-digit currency headwind, while acquisitions/divestitures added slightly. For full-year 2025, non-GAAP adjusted diluted EPS is expected to land toward the high end of the previously guided $7.70 to $7.80a range. Management highlighted strength in Bioprocessing (consumables up high-single digits, equipment up mid-single digits), better-than-expected Life Sciences and Diagnostics results, and mid-single-digit growth at SCIEX.
The slides also introduce initial 2026 expectations of 3%b to 6% core revenue growth, with adjusted operating profit margin expansion of more than 100 basis points and adjusted EPS growth in the high-single digits. For investors, the key takeaways are the upbeat tone on Q4 execution and the initial 2026 framework, which signals a gradual recovery toward long-term high-single-digit core growth. Investors should note that these are estimates ahead of the full earnings release, which is scheduled for January 28, 2026, and that the company's net debt to adjusted EBITDA was about 2.5x as of September 2025, leaving capacity for acquisitions.
02—Key points
Key Highlights
- Q4 2025 total revenue expected to grow in the mid-single-digit percent range year-over-year.
- Q4 2025 non-GAAP core revenue growth expected toward the high end of the low-single-digit guidance; currency was a low-single-digit headwind.
- FY 2025 non-GAAP adjusted diluted EPS expected toward the high end of the $7.70 to $7.80 guidance range.
- Bioprocessing remained a standout: consumables up high-single digits and equipment up mid-single digits in Q4; Diagnostics showed good momentum.
- Initial 2026 outlook: core revenue growth of 3% to 6%, adjusted operating profit margin expansion of more than 100 bps, and high-single-digit adjusted EPS growth.
- Management reiterated long-term capacity for strategic M&A, with net debt to adjusted EBITDA around 2.5x as of September 2025 versus about 2.0x post-Cytiva.
- Full Q4 and FY 2025 results and earnings call are scheduled for January 28, 2026.
03—Questions
Frequently Asked Questions
Did Danaher change its full-year 2025 guidance?
Not formally. Management said full-year 2025 adjusted diluted EPS is expected toward the high end of the previously announced $7.70 to $7.80 range, and Q4 core revenue growth is expected toward the high end of its low-single-digit guidance. These are preliminary estimates, and final results will be reported on January 28, 2026.
What drove the Q4 2025 performance?
Management cited continued strength in Bioprocessing, with consumables up high-single digits and equipment up mid-single digits, along with better-than-expected Life Sciences and Diagnostics revenue. Life Sciences benefited from improving instrument performance, including mid-single-digit growth at SCIEX. Currency translation was a low-single-digit headwind to reported sales growth.
What is the initial 2026 outlook?
The slides indicate initial 2026 expectations of 3% to 6% core revenue growth, more than 100 basis points of adjusted operating profit margin expansion, and high-single-digit adjusted EPS growth. Management expects core growth to accelerate as end markets recover and gradually move toward its long-term high-single-digit core growth target.
Is this 8-K a material new disclosure about the company's finances?
The filing is largely a preliminary update furnished under Item 2.02, not a set of audited financial statements. The information is not deemed 'filed' under the Exchange Act, and it provides estimates in advance of the full earnings release. Investors should treat the figures as unaudited and subject to change.
How much capacity does Danaher have for acquisitions?
Management said it has significant capital deployment capacity. Net debt to adjusted EBITDA was about 2.5x as of September 26, 2025, up from roughly 2.0x after the Cytiva acquisition, which still leaves room for strategic M&A. Risks include integration, goodwill impairment, and the debt burden on operations and liquidity.
04—Continue